drugset / Trial / NCT00604318

Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer

NCT00604318

RandomizedCrossoverDouble-blindTreatment

Summary

To evaluate quality of life in patients after 10 days pause of thyroid medication (Liothyronine) compared to treatment with recombinant TSH (Thyrogen) before radioiodine uptake and treatment in a double-blinded, randomised cross-over design.

Timeline

Start
2008-02
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator rhTSH Protein / enzyme biologic 0.9 mg Other

Indications